Case Report
BibTex RIS Cite

Makroprolaktinoma da Kabergolin Tedavisinin Etkinliği

Year 2017, , 145 - 148, 30.09.2017
https://doi.org/10.31832/smj.310363

Abstract

Hipotalamus-hipofiz aksının en sık rastlanan
endokrin bozukluğu hiperprolaktinemidir.  Prolaktinoma çocukluk çağı ve adolesan dönemde
 hipofizer adenomlarının en sık görülen
tipidir. Çocukluk çağında ve adolesanda görülen hipofizer  tümörlerin yaklaşık %40’ını  prolaktinoma oluşturmaktadır. Klinik
bulguları amenore, anovulasyon, infertilite, hipogonadizm, galaktore ve adet
düzensizliğidir.  Tedavide ilk seçenek
dopamin agonistleridir (bromokriptin, kabergolin). Biz amenore ve galaktore
şikayetleri ile başvuran, prolaktinomalı 15 yaşında kız hastayı sunmayı  amaçladık.

References

  • 1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology 2006; 65: 265-273. 2. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005;:8:3 -6. 3. Thibaud E, Samara-Boustani D, Duflos-Cohade C. Meno-metrorraghia in adolescents. Arch Pediatr 2008;15:584-585. 4. Gillam MP, Molitch ME; Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534. 5. Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 2009;23:575-96. 6. Toprak D. Prolaktinoma: Olgu Sunumu ve Hiperprolatinemiye Güncel Yaklaşım. Türk Aile Hek Derg 2005;9:85-89 7. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999;44:1075-84. 8. Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol 2001;54:139-150. 9. Sonino N, Navarrini C, Ruini C, Fallo F, Boscaro M, Fava GA. Life events in the pathogenesis of hyperprolactinemia. Eur J Endocrinol 2004; 151:61-65 10. Huang AP, Yang SH, Yang CC, Kuo MF, Wu MZ, Tu YK. Malignant prolactinoma with craniospinal metastasis in a 12-year-old boy. J Neurooncol 2008;90:41-46. 11. Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary, 2003;5:55-65. 12. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 2002;20:365-74 13. Webster J. Clinical management of prolactinomas. Clin Endocrinol Metab1999; 13: 395-408
Year 2017, , 145 - 148, 30.09.2017
https://doi.org/10.31832/smj.310363

Abstract

References

  • 1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology 2006; 65: 265-273. 2. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005;:8:3 -6. 3. Thibaud E, Samara-Boustani D, Duflos-Cohade C. Meno-metrorraghia in adolescents. Arch Pediatr 2008;15:584-585. 4. Gillam MP, Molitch ME; Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534. 5. Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 2009;23:575-96. 6. Toprak D. Prolaktinoma: Olgu Sunumu ve Hiperprolatinemiye Güncel Yaklaşım. Türk Aile Hek Derg 2005;9:85-89 7. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999;44:1075-84. 8. Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol 2001;54:139-150. 9. Sonino N, Navarrini C, Ruini C, Fallo F, Boscaro M, Fava GA. Life events in the pathogenesis of hyperprolactinemia. Eur J Endocrinol 2004; 151:61-65 10. Huang AP, Yang SH, Yang CC, Kuo MF, Wu MZ, Tu YK. Malignant prolactinoma with craniospinal metastasis in a 12-year-old boy. J Neurooncol 2008;90:41-46. 11. Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary, 2003;5:55-65. 12. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 2002;20:365-74 13. Webster J. Clinical management of prolactinomas. Clin Endocrinol Metab1999; 13: 395-408
There are 1 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Articles
Authors

Derya Buluş

Publication Date September 30, 2017
Submission Date May 3, 2017
Published in Issue Year 2017

Cite

AMA Buluş D. Makroprolaktinoma da Kabergolin Tedavisinin Etkinliği. Sakarya Tıp Dergisi. September 2017;7(3):145-148. doi:10.31832/smj.310363

30703

SMJ'de yayınlanan makaleler, Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı kapsamında lisanslanır